Action Point Financial Planning’s Denali Therapeutics DNLI Stock Holding History

Action Point Financial Planning’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$849	Buy	+33	New	+$678	﹤0.01%	2525

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Action Point Financial Planning's DNLI Position: Q2 2026 in Review

Action Point Financial Planning opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 33 shares worth $849. The stake represents ﹤0.01% of the portfolio and ranks #2525 among its holdings.

290 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Action Point Financial Planning held 33 shares of Denali Therapeutics worth $849 as of Q2 2026.
Denali Therapeutics was a new Action Point Financial Planning position in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Action Point Financial Planning's portfolio in Q2 2026, its #2525 holding.
290 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Action Point Financial Planning's 13F filing for Q2 2026, filed 14 Aug 2026.